Systematic review / meta-analysis / 2012
Reishi mushroom as an adjunct to cancer therapy showed potential immune and response benefits
A meta-analysis of five randomized trials examined Ganoderma lucidum in cancer care. Combining the mushroom with chemotherapy or radiotherapy increased the likelihood of a positive response compared to conventional therapy alone (RR 1.50, 95% CI 0.90 to 2.51). Furthermore, supplementation raised CD3, CD4, and CD8 percentages by 3.91%, 3.05%, and 2.02%, while quality of life was relatively improved in four studies.
- Study type
- Meta-analysis of randomized controlled trials
- Who was studied
- Cancer patients across 5 randomized controlled trials
- What was measured
- Tumour response, host immune function, and quality of life
THE PAPER
Ganoderma lucidum (Reishi mushroom) for cancer treatment.
Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Cochrane Database Syst Rev, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.